Correlation between serum inflammatory factor interleukin-35 and the development of prostate cancer
-
摘要: 目的:探究血清IL-35介导的炎症反应及可能的免疫逃逸在前列腺癌发生的临床应用。方法:选取2016年1月~2017年12月我院收治的前列腺患者64例,其中前列腺增生31例(前列腺增生组),前列腺癌33例(前列腺癌组)。同时采取Gleason评分对前列腺癌患者进行分组(≥7分组和<7分组)。检测所有患者血清IL-35水平,同时评估IL-10和IL-6水平及免疫系统指标(CD4+/CD8+)变化。结果:前列腺癌组患者血清IL-35、IL-10及IL-6水平高于前列腺增生组,外周血CD4+/CD8+水平低于前列腺增生组(P<0.05);此外,IL-35、IL-10、IL-6水平及CD4+/CD8+与PSA、Gleason评分呈正相关性(P<0.05)。结论:前列腺癌组患者的血清IL-10、IL-6水平及CD4+/CD8+与前列腺增生组比较差异有统计学意义(P<0.05),可能与IL-35介导的炎症反应及免疫逃逸存在一定的相关性,可见IL-35在临床评估前列腺癌患者病情方面有重要的潜在应用价值。Abstract: Objective: To investigate the clinical application of serum IL-35 mediated inflammatory response and immune escape in the development of prostate cancer. Method: Sixty-four cases with prostate disease in our hospital were selected from January 2016 to December 2017. There were 31 cases of benign prostatic hyperplasia and 33 cases of prostate cancer. Prostate cancer patients were grouped by Gleason score(≥7 group; <7 group). Serum IL-35 level was measured in all patients. IL-10 and IL-6 levels and immune system parameters(CD4+/CD8+) were also assessed. Result: The levels of serum IL-35, IL-10 and IL-6 in cases with adenocarcinoma were higher than those in benign prostatic hyperplasia group. The level of CD4+/CD8+in peripheral blood was lower than that in benign prostatic hyperplasia group(P<0.05). In addition, IL-35, IL-10, IL-6 and CD4+/CD8+were positively correlated with PSA and Gleason scores(P<0.05).Conclusion: Serum levels of IL-10, IL-6 and CD4+/CD8+in cases with prostate cancer are different from those with benign prostatic hyperplasia, which may be related to IL-35-mediated inflammatory reaction and immune escape. IL-35 shows important application values in the condition of cases with prostate cancer.
-
Key words:
- prostate cancer /
- inflammatory factors /
- immune escape /
- clinical application /
- IL-35
-
-
[1] 罗鹏,赵松涛,王涛,等.肥胖、血脂与前列腺癌发生及进展的关系[J].实用医院临床杂志,2017,14(6):16-20.
[2] Pang C,Guan Y,Li H,et al.Urologic cancer in China[J].Jpn J Clin Oncol,2016,46(6):497-501.
[3] 韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[4] 王烨菁,傅忠星,王珏,等.2004-2011年上海市卢湾区社区人群前列腺癌发病与死亡分析[J].中国肿瘤,2017,26(6):438-441.
[5] Zhu Y,Wang HK,Qu YY,et al.Prostate cancer in East Asia:evolving trend over the last decade[J].Asian J Androl,2015,17(1):48-57.
[6] 苏欢.血清IL-6与前列腺癌相关性的临床评价及其功能的初步探究[C].南京:东南大学,2017.
[7] 谢家恩,陈舜琦,王明川,等.前列腺癌腹腔镜手术与经典手术的比较[J].检验医学与临床,2017,14(14):2103-2104.
[8] Raymond E,O'Callaghan ME,Campbell J,et al.An appraisal of analytical tools used in predicting clinical out-comes following radiation therapy treatment of men with prostate cancer:a systematic review[J].Radiat Oncol,2017,12(1):56.
[9] 刘志坚,谭慭莘,王德林,等.腹腔镜前列腺根治术与耻骨后前列腺根治术的住院费用比较分析[J].中国微创外科杂志,2017,17(2):171-173,183.
[10] Gu X,Tian T,Zhang B,et al.Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer[J].Tumour Biol,2015,36(4):2651-2656.
[11] Zhang Y,Sun H,Wu H,et al.Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma[J].Contemp Oncol(Pozn),2015,19(2):120-124.
[12] Zhao N,Li H,Yan Y,et al.Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4+T cell function[J].Cell Immunol,2017,312:61-66.
[13] Zou JM,Qin J,Li YC,et al.IL-35 induces n2 phenotype of neutrophils to promote tumor growth[J].Oncotarget,2017,8(20):33501-33514.
[14] Yamanishi Y,Boyle DL,Rosengren S,et al.Regional analysis of p53 mutations in rheumatoid arthritis synovium[J].Proc Natl Acad Sci USA,2002,99(15):10025-10030.
[15] Tao Q,Chen T,Tao L,et al.IL-15 improves the cytotoxicity of cytokineinduced killer cells against leukemia cells by upregulating CD3+CD56+cells and downregulating regulatory T cells as well as il-35[J].J Immunother,2013,36(9):462-467.
[16] 尹洁,王懿娜.IL-35调控恶性肿瘤发生发展机制的研究进展[J].中国肿瘤临床,2018,45(10):529-534.
[17] 张威,王璐,徐万海.PI3K/Akt途径在前列腺癌中的治疗前景[J].临床泌尿外科杂志,2017,32(12):934-937.
[18] 慕玉东,贺林,原荣,等.IL-4和IL-6在前列腺癌组织中的表达及其临床意义[J].现代肿瘤医学,2018,26(14):2214-2217.
-
计量
- 文章访问数: 179
- PDF下载数: 97
- 施引文献: 0
下载: